Three large 2024 studies — a 50-million-person database analysis, a 29,000-patient cohort, and a landmark meta-analysis — found PDE5 inhibitor use associated with 22–30% reductions in cardiovascular events and mortality. Here is what the data actually says and what it means.
In 2024, three substantial datasets converged on a consistent finding: men who use tadalafil have meaningfully lower rates of heart attacks, cardiovascular events, and all-cause death than men who do not.
This is not a hypothesis. It is a pattern showing up in the largest population databases in medicine.
Understanding why requires understanding what tadalafil actually does to the vascular system — and why the endothelium is a better longevity target than most people realize.
Your endothelium is a single-cell-thick layer lining every blood vessel in your body. By surface area it is one of the largest organs you have — roughly 60,000 miles of vasculature covered by approximately 7 trillion cells.
When endothelial function is normal, all of this happens seamlessly. When it degrades — through oxidative stress, insulin resistance, hypertension, smoking, age — the downstream consequences reach every organ in the body.
Endothelial dysfunction is now recognized as the earliest measurable step in cardiovascular disease. It precedes atherosclerosis by years. It is detectable long before any symptoms, long before any coronary calcification, long before any clinical event. Flow-mediated dilation (FMD) of the brachial artery — a non-invasive ultrasound measurement — is the clinical gold standard for quantifying endothelial function, and impaired FMD has been validated as an independent predictor of cardiovascular events in prospective studies.
PDE5 (phosphodiesterase type 5) is an enzyme expressed throughout vascular smooth muscle. Its function is to degrade cyclic GMP (cGMP) — the downstream messenger of nitric oxide. cGMP is what actually causes smooth muscle relaxation and vasodilation.
The sequence is: nitric oxide → activates guanylate cyclase → cGMP increases → smooth muscle relaxes → vessels dilate.
PDE5 terminates this signal by breaking down cGMP. In endothelial dysfunction, two problems coexist: reduced NO production and increased PDE5 activity. The result is a system where less NO is made and what little cGMP is generated is broken down faster.
Tadalafil blocks PDE5. This does not fix the upstream NO deficiency directly — it protects and amplifies whatever cGMP signal exists. At 5 mg daily, with a half-life of 17.5 hours, it maintains continuous PDE5 inhibition throughout the vascular system.
Principal investigator Robert Kloner — one of the world's leading cardiovascular pharmacologists — led a retrospective observational cohort using a large US commercial insurance claims database. The study enrolled more than 29,000 men with erectile dysfunction who had no prior MACE.
Outcome: Tadalafil use was associated with significantly lower rates of MACE (composite of cardiovascular death, MI, coronary revascularization, unstable angina, heart failure, and stroke) and all-cause mortality. The result showed a clear dose-response relationship: men with the highest cumulative tadalafil exposure had a MACE hazard ratio of 0.40 — a 60% reduction compared to non-users.
A dose-response relationship is one of the strongest indicators of causality in observational data. It reduces — though does not eliminate — the concern that tadalafil users are simply healthier people to begin with.
The TriNetX database covers 50 million US patients. This analysis identified men aged 40 and older prescribed tadalafil or sildenafil after an erectile dysfunction diagnosis between 2004 and 2021 and followed them for 3 years.
Outcome: PDE5 inhibitor use was associated with significantly reduced all-cause mortality, cardiovascular disease events, and dementia compared to matched controls. The dementia finding is particularly notable — it aligns with the cerebral perfusion mechanism and with earlier preclinical data showing PDE5 inhibition improves cerebrovascular function.
Systematic review and meta-analysis of RCTs and observational studies evaluating PDE5 inhibitor impact on hard cardiovascular endpoints. Minimum follow-up of 6 months.
Outcome: PDE5 inhibitor use associated with a 22% reduction in MACE and a 30% reduction in all-cause mortality in men with elevated baseline cardiovascular risk.
The population data is supported by mechanistic evidence from smaller, higher-quality studies.
Rosano et al., European Urology 2005 (PMID 15661417): 32 men with more than two cardiovascular risk factors (10-year CVD risk >20%) randomized to tadalafil versus placebo. Tadalafil significantly improved brachial artery FMD, increased plasma nitric oxide, and reduced endothelin-1 (a potent vasoconstrictor whose elevation is independently associated with cardiovascular mortality).
Aversa et al., Sexual Medicine 2021 (PMID 33818935): 60 men with ED and concomitant cardiovascular pathology. Daily 5 mg tadalafil directly compared to 20 mg on-demand. Daily low-dose was superior on every endothelial marker — NO, endothelin-1, vascular stiffness index, FMD. This result is important because it validates the specific dosing protocol used in longevity practice.
El-Shaer et al., Sexual Medicine 2023 (PMID 37506991): Brachial FMD measured at baseline and after 3 months of PDE5 inhibitor therapy. Significant FMD improvement. Pearson correlation of r = 0.959 between FMD changes and erectile function changes — confirming that the vascular and sexual improvements are driven by the same endothelial mechanism.
The epidemiological reason ED functions as a cardiovascular risk factor is instructive for understanding the longevity rationale for tadalafil.
The penile arteries (internal pudendal arteries) have a smaller diameter than the coronary arteries. Endothelial dysfunction and early atherosclerosis impair smaller vessels first — because the same degree of lumen narrowing produces proportionally greater flow restriction in smaller tubes. This is why erectile dysfunction typically precedes symptomatic coronary artery disease by 2–5 years.
Tadalafil treating ED is therefore tadalafil treating the vascular symptom of endothelial dysfunction — in the most endothelially sensitive vascular bed. That the drug simultaneously improves FMD of the brachial artery, reduces systemic blood pressure, lowers endothelin-1, and reduces MACE in population studies is consistent with a drug treating the same underlying pathology throughout the entire vascular tree.
The large 2024 studies are observational. Randomized controlled trial data with hard longevity endpoints does not exist for tadalafil in healthy adults — the same gap that exists for rapamycin, metformin, and virtually every longevity intervention.
Healthy user bias is a legitimate concern in observational PDE5 inhibitor data. Men who are prescribed and consistently take tadalafil may on average have better healthcare engagement, higher socioeconomic status, and healthier baseline behaviors than non-users.
The dose-response relationship in the Kloner data reduces this concern somewhat. Healthy user bias would be expected to be similar across tadalafil dose groups — but a dose-response pattern within users, where higher cumulative exposure produces better outcomes, is more consistent with pharmacological effect than confounding.
The mechanism is well-validated in RCTs. The population outcomes are consistent with the mechanism. The drug has 20 years of safety data at the doses in question. The benefit-risk calculation at 5 mg daily in a healthy adult without contraindications is favorable by most assessments in longevity medicine.
The population data is strongest in men with elevated baseline cardiovascular risk — which in practice means most men over 40 with any of: hypertension, dyslipidemia, insulin resistance, obesity, family history of premature CAD, or a history of smoking.
Healthy men under 40 with no cardiovascular risk factors have less direct evidence but the same mechanistic rationale. Whether the benefit-risk calculation is favorable at younger ages and lower baseline risk is a conversation for an individual physician.
The mechanism applies equally to women — PDE5 is expressed in female vascular tissue, and tadalafil is FDA-approved for pulmonary arterial hypertension in both sexes. Off-label use in women for cardiovascular longevity is less common but not without mechanistic basis.
Is there any RCT evidence for tadalafil reducing MACE in healthy adults?
No dedicated RCT with MACE as a primary endpoint in healthy adults exists. The evidence base is mechanistic RCTs (FMD, biomarkers) plus large observational studies with hard outcomes. The FDA has approved tadalafil for PAH based on cardiovascular endpoints — but that is a disease indication, not healthy longevity.
Does tadalafil affect blood pressure medication?
At 5 mg daily, tadalafil produces a modest blood pressure reduction (typically 4–8 mmHg systolic in people with normal baseline BP). In people already on antihypertensive medications, additive effects are possible. Alpha-blockers specifically require caution — the combination can produce symptomatic hypotension. Discuss all medications with your physician before starting.
Can tadalafil be taken indefinitely?
The clinical data covers use over several years with no evidence of tolerance or cumulative harm at the 5 mg daily dose. The FDA approval for BPH at 5 mg daily is not time-limited. Longevity physicians typically treat it as an ongoing maintenance protocol rather than a finite course.
How long until endothelial function measurably improves?
In the RCT data, significant changes in FMD and biomarkers (NO, endothelin-1) were measurable at 4–8 weeks of daily dosing. Blood pressure reduction is typically seen sooner — within 1–2 weeks in many patients.